GET DAILY SIGNALSUCB SA (UCB) Reports Strong 2025 Results with Revenue Up +26%
Key Takeaways
- UCB SA reported full-year 2025 revenue of €7.74 billion, up 26% from €6.15 billion in 2024.
- Net income climbed 46% to €1.56 billion, while diluted earnings per share (EPS) rose to €8.03 from €5.48.
- Core EPS, a non-standard measure of underlying profitability, doubled to €9.99 from €4.98.
- Adjusted EBITDA jumped 79% to €2.64 billion, lifting the margin to 34%.
- Five growth brands generated more than €3.3 billion in combined net sales, led by Bimekizumab (BIMZELX) topping €2.2 billion.
- Management issued 2026 guidance that trailed some consensus estimates, signaling a more measured growth outlook.
Why These Results Stand Out
UCB SA's full-year 2025 results represent a key turning point for the Belgian biopharmaceutical group. After dealing with patent expirations and portfolio adjustments in recent years, the company has relied on a fresh set of immunology and neurology products to drive renewed growth. The 26% revenue increase and near-doubling of adjusted EBITDA show how well its five main growth drivers are now compensating for declines in older products such as CIMZIA. For investors, the report highlights not just the strength of 2025 performance but also how UCB might maintain this pace amid rising competition and U.S. pricing pressures.
The Numbers in Detail
UCB SA reported full-year 2025 revenue of €7.74 billion, a 26% increase from €6.15 billion in 2024. Net sales rose 32% to €7.39 billion. Net income reached €1.56 billion, up 46% from €1.07 billion, while diluted EPS from continuing operations came in at €8.03 versus €5.48 a year earlier. Core EPS, which adjusts for items such as amortization of intangibles linked to sales, doubled to €9.99 from €4.98. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Profitability improved sharply, with adjusted EBITDA climbing 79% to €2.64 billion and the adjusted EBITDA margin expanding to 34% from 24%. The five growth drivers — BIMZELX (bimekizumab), EVENITY (romosozumab), FINTEPLA (fenfluramine), RYSTIGGO (rozanolixizumab), and ZILBRYSQ (zilucoplan) — more than doubled their combined net sales to over €3.3 billion. BIMZELX alone exceeded €2.2 billion in annual sales. On a fourth-quarter basis, UCB beat analyst estimates on both revenue and EPS, though its forward guidance drew closer scrutiny.
Market Reaction
Investor reaction to UCB's report reflected a tension between impressive 2025 execution and a more cautious 2026 outlook. The full-year figures, including the 79% surge in adjusted EBITDA and the doubling of core EPS, validated the company's growth strategy and highlighted the success of BIMZELX. However, management's guidance for 2026 — high-single-digit to low-double-digit revenue growth and high-single-digit to high-teens EBITDA growth at constant exchange rates — was viewed by some analysts as falling short of consensus expectations. Sentiment heading into the print had been positive given the momentum of the growth brands, but the softer-than-anticipated forward view tempered enthusiasm and underscored concerns about U.S. pricing pressure and upcoming competition.
Forward Outlook
Looking ahead, investors will focus on whether UCB can sustain the trajectory of its growth portfolio while managing a shifting competitive landscape. The company expects revenue growth in the high-single-digit to low-double-digit range at constant exchange rates (CER) in 2026, with adjusted EBITDA growth in the high-single-digit to high-teens range at CER.
Several factors warrant close attention. First, BIMZELX remains the primary growth engine, but management has flagged that net pricing will likely moderate as access expands in the United States. Second, the legacy franchise BRIVIACT faces an expected loss of exclusivity in the U.S. and Europe during 2026, which could pressure sales. Third, U.S. pricing dynamics tied to Medicare Part D redesign and 340B programs add further uncertainty to revenue realization.
On the pipeline front, UCB received U.S. Food and Drug Administration (FDA) approval for KYGEVVI, a first treatment for TK2 deficiency, and continues to evaluate higher-risk programs such as bepranemab in Alzheimer's disease. The company's clean balance sheet, highlighted by management, also provides room for potential business development. Investors should monitor launch execution, pricing trends, and pipeline progress as the key drivers of the 2026 outlook.
Using AI Tools in My Research
From what I see, tools like Tickeron’s AI Screener help me quickly compare performance metrics across peers and spot patterns in the biotech space that might otherwise take hours to identify manually. I find it useful when reviewing results like these to cross-check industry positioning before drawing conclusions on valuation or growth sustainability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UCB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for UCB turned positive on October 15, 2026. Looking at past instances where UCB's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UCB's RSI Oscillator exited the oversold zone, 17 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 58 cases where UCB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where UCB advanced for three days, in 160 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
UCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UCB as a result. In 51 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
UCB moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. UCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock worse than average.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.088) is normal, around the industry mean (1.229). P/E Ratio (11.039) is within average values for comparable stocks, (13.102). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (1.190). Dividend Yield (0.031) settles around the average of (0.036) among similar stocks. P/S Ratio (3.890) is also within normal values, averaging (3.738).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a regional bank
Industry RegionalBanks
Advertisement